积石成山丨中国黑色素瘤代表性论著阶段总结

Chin J Cancer Res A phase II study of fotem ustine plus Dacarbazine with Dendritic Cell Vaccines as first-Line therapy for Chinese patients with advanced acral lentiginous melanoma（2009）

Eur J Cancer  A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients （2011）

J Clin Oncol  Phase II, open-label, single-arm trial of Imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification （2011）

Mol Ther A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma （2012）

Clin Cancer Res  Phase II randomized trial comparing high-dose IFN-α2b with Temozolomide plus Cisplatin as systemic adjuvant therapy for resected mucosal melanoma （2013）

Ann Oncol Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial (2017)

BMC Cancer Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study (2018)

Transl Oncol  A Phase Ib study of Pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151) (2019)

J Clin Oncol Axitinib in combination with Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: An open-label phase IB trial (2019)

Eur J Cancer  Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma (2020)

Clin Cancer Res  Safety, efficacy and biomarker analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial (2020)

J Immunother Cancer  Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study（2020）

J Clin Oncol Randomized phase II study of Bevacizumab in combination with Carboplatin plus Paclitaxel in patients with previously untreated advanced mucosal melanoma (2021)

Clin Cancer Res  Large-scale analysis of KIT aberrations in Chinese patients with melanoma （2011）

J Clin Oncol Major response to Everolimus in melanoma with acquired Imatinib resistance （2012）

Eur J Cancer Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort （2012）

Clin Cancer Res Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib （2013）

Clin Cancer Res  Analysis of mTOR gene aberrations in melanoma patients and evaluation of their sensitivity to PI3K-AKT-mTOR pathway inhibitors （2015）

Eur J Cancer  GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis （2016）

Clin Cancer Res  Frequent genetic aberrations1 in the CDK4 pathway in acral melanoma indicate the potential for CDK4/6 inhibitors in targeted therapy （2017）

J Clin Invest  MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma (2017)

Clin Cancer Res MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients：a retrospective study of 2793 cases (2017)

Ann Oncol The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients (2017)

Nature  PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (2017)

Eur J Cancer  Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor (2018)

Clin Cancer Res  Genetic aberrations in the CDK4 pathway  are associated with innate resistance to 2 PD-1 blockade in Chinese patients with non-cutaneous melanoma (2019)

Eur J Cancer  Identification of a functional polymorphism within the 30-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma (2019)

Theranostics MicroRNA-23a-3p inhibits mucosal melanoma growth and progression through targeting adenylate cyclase 1 and attenuating cAMP and MAPK pathways (2019)

J Exp Clin Cancer Res miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy (2019)

J Hematol Oncol Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients (2019)

Nat Commun Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets (2019)